The recurrence rate in women with ER positive/HER2 negative early-stage node negative breast cancer is generally low and many patients do not need adjuvant chemotherapy. However, Myriad Genetics believes every patient matters and deserves to know their true risk of breast cancer recurrence to help guide shared treatment decision-making.
EndoPredict identifies the largest low-risk group of node negative women that can avoid chemotherapy, while accurately recognizing high-risk patients that will benefit from chemotherapy.1-5
It is the only second generation breast cancer prognostic test validated for premenopausal AND postmenopausal women with early-stage breast cancer that is ER positive, HER2 negative, node negative or positive1-7 – and the first second generation test with level of evidence 1A data.8,9
If you are a patient, please ask your doctor if the EndoPredict test is right for you, or visit our patient homepage for more information.
In the TransATAC head-to-head comparison, EndoPredict identifies the largest group at true low-risk of recurrence in patients with node negative breast cancer, with a recurrence risk of less than 10%.3,10 It’s also significantly more accurate than first generation tests like the Oncotype DX® test.1,10
Learn more about EndoPredict’s superior accuracy versus first generation tests.
The higher the C-index, the greater the prognostic power
The C-index is a statistical tool used to evaluate the accuracy of an algorithm and therefore the prognostic power of a test by comparing predicted outcomes with actual events. A high C-index indicates results cannot be chance (as in the flip of a coin which is chance and scores 0.5) but are due to the accuracy of the test. Results are independent of test cut-off values.
EndoPredict is the only second generation test validated for both node positive and node negative breast cancer recurrence in premenopausal women with ER positive/HER2 negative early-stage breast cancer.6
A recent study of premenopausal patients demonstrated that EPclin Risk Score is strongly associated with 10-year distant recurrence free survival – regardless of nodal status.6
For node negative disease, this was shown in a subset analysis of 323 women from this study, after a median follow-up of 9.7 years.6
“In combination with established clinical and pathological factors, EndoPredict may be used for predicting outcome and aiding adjuvant therapy decision-making in [ER positive] HER2-negative patients that are either lymph node negative or lymph node positive…”11
“[EndoPredict] may be used to gain additional prognostic and/or predictive information to complement pathologic evaluation and to predict chemotherapy benefit for N0 and N+ (1-3 positive lymph nodes) disease in uncertain cases.“12
Level of evidence 1B
Recommended for postmenopausal women with N0/N+ (1-3 nodes) to guide adjuvant endocrine and chemotherapy decisions.13
EndoPredict Breast Cancer Prognostic Test is available to order by clinicians via numerous local labs in your country or outside of the EU also via Myriad Genetics’ central laboratory in Salt Lake City, USA.